Compare VIV & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIV | EXAS |
|---|---|---|
| Founded | 1973 | 1995 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6B | 19.7B |
| IPO Year | 1998 | 2000 |
| Metric | VIV | EXAS |
|---|---|---|
| Price | $15.60 | $103.78 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 17 |
| Target Price | $13.70 | ★ $86.62 |
| AVG Volume (30 Days) | 855.9K | ★ 1.8M |
| Earning Date | 02-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 80.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,000.00 |
| Revenue This Year | $9.26 | $15.37 |
| Revenue Next Year | $5.71 | $12.41 |
| P/E Ratio | $22.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.51 | $38.88 |
| 52 Week High | $16.95 | $104.02 |
| Indicator | VIV | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 60.15 |
| Support Level | $15.28 | $102.95 |
| Resistance Level | $16.63 | $103.85 |
| Average True Range (ATR) | 0.40 | 0.32 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 15.57 | 77.57 |
Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 102 million customers, which is equal to about 39% market share. The firm is strongest in the postpaid business, where it has 68 million customers, or about 41% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and also owns an extensive fiber network across the country. The firm provides internet access to 8 million households on this network. The firm also sells pay-TV and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 9% of total revenue.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.